114 related articles for article (PubMed ID: 23485655)
1. Characterization of neovascular age-related macular degeneration patients with outer retinal tubulations.
Faria-Correia F; Barros-Pereira R; Queirós-Mendanha L; Fonseca S; Mendonça L; Falcão MS; Brandão E; Falcão-Reis F; Carneiro AM
Ophthalmologica; 2013; 229(3):147-51. PubMed ID: 23485655
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
3. Short-term progression of wet AMD and correlation with 1-year treatment results.
Munk M; Kiss C; Sulzbacher F; Eisenkölbl S; Sacu S; Kalcher K; Jampol L; Schmidt-Erfurth U
Acta Ophthalmol; 2012 Sep; 90(6):e420-7. PubMed ID: 22339794
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
Mathew R; Richardson M; Sivaprasad S
Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
[TBL] [Abstract][Full Text] [Related]
5. [Morphology of outer retinal tubulations in the outcome of exudative age-related macular degeneration according to optical coherence tomography angiography].
Kurysheva NI; Pererva OA; Ivanova AA
Vestn Oftalmol; 2021; 137(4):72-80. PubMed ID: 34410060
[TBL] [Abstract][Full Text] [Related]
6. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
Bloch SB; Lund-Andersen H; Sander B; Larsen M
Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
[TBL] [Abstract][Full Text] [Related]
7. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
Lee SJ; Koh HJ
Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
[TBL] [Abstract][Full Text] [Related]
8. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
9. Association between foveal microstructure and visual outcome in age-related macular degeneration.
Shin HJ; Chung H; Kim HC
Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
[TBL] [Abstract][Full Text] [Related]
10. Outer retinal tubulations response to anti-VEGF treatment.
Espina M; Arcinue CA; Ma F; Camacho N; Barteselli G; Mendoza N; Ferrara N; Freeman WR
Br J Ophthalmol; 2016 Jun; 100(6):819-23. PubMed ID: 26423451
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
12. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration.
Brown DM; Tuomi L; Shapiro H;
Retina; 2013 Jan; 33(1):23-34. PubMed ID: 23073338
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
14. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
16. Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up.
Marques IP; Fonseca P; Luz Cachulo M; Pires I; Figueira J; Faria de Abreu JR; Silva R
Ophthalmologica; 2013; 229(3):158-67. PubMed ID: 23485818
[TBL] [Abstract][Full Text] [Related]
17. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
[TBL] [Abstract][Full Text] [Related]
18. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
19. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
